ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ProKidney Corp.NASDAQ: PROK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $33.84M rose 24.1% year over year, ahead of the -5.5% change in trailing-twelve-month research & development. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.
Context
- Research & development amounted to 12779.7% of revenue in FY2025, down 155204.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +24.1% holds above the trailing-twelve-month pace of -5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 114.12M USD
- Year-over-year change
- -10.6%
- 4-year CAGR
- +25.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 114.12M | -10.6% |
| FY2024 | 2024-12-31 | 127.67M | +19.6% |
| FY2023 | 2023-12-31 | 106.71M | +30.0% |
| FY2022 | 2022-12-31 | 82.07M | +77.4% |
| FY2021 | 2021-12-31 | 46.26M | — |
Research & Development vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 research & development of $120.7M is the 2nd highest of the 7 companies compared; the peer median is $50.63M.
- Its year-over-year change of -5.5% is the 5th highest of 6, against a peer median of +28.1%.
- Research & development amounts to 13577.3% of revenue for PROK, versus a peer median of 37.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $245.55M | +16.8% | -3.2% | 37.7% | |
| LTM Mar 2026 | $120.7M | -5.5% | +11.6% | 13577.3% | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| LTM Mar 2026 | $74.32M | +33.9% | +24.8% | 17.4% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $8.57M | -44.2% | -9.8% | — | |
| LTM Dec 2024 | $927 | — | -17.2% | — | |
| Peer median (excluding PROK) | $50.63M | +28.1% | +2.0% | 37.7% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 76K | 893K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 76K | 893K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
| Selling, General & Admin | 8.86M | 70.94M | 44.82M | 56.08M | 51.78M |
| Operating Expenses | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| EBITDA | (53.12M) | (143.99M) | (125.59M) | (158.49M) | (144.62M) |
| EBITDA Margin | — | — | — | -208542.1% | -16194.7% |
| Operating Income | (55.11M) | (153.01M) | (151.52M) | (183.68M) | (165.01M) |
| Operating Margin | — | — | — | -241678.9% | -18477.8% |
| Interest Income | 2K | 5.98M | 22.08M | 19.75M | 13.81M |
| Interest Expense | 0 | 215K | 12K | 9K | 4K |
| Other Income / Expenses | 2K | 5.77M | 22.07M | 19.74M | 13.81M |
| Income Before Tax | (55.11M) | (147.24M) | (129.45M) | (163.93M) | (151.2M) |
| Pre-Tax Margin | — | — | — | -215701.3% | -16931.5% |
| Income Tax Expense | 38K | 896K | 6M | (598K) | 414K |
| Net Income | (55.15M) | (108.03M) | (35.47M) | (61.19M) | (68.99M) |
| Net Margin | — | — | — | -80507.9% | -7725.2% |
| EPS (Basic) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| EPS (Diluted) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| Weighted Avg Shares | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Weighted Avg Shares (Diluted) | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.